Cai Jing Wang·2026-03-30 14:50Core Viewpoint - Kailaiying reported a total revenue of 6.67 billion yuan for 2025, marking a year-on-year growth of 14.91% [1] Financial Performance - The net profit attributable to the parent company reached 1.133 billion yuan, an increase of 19.35% year-on-year [1] - Basic earnings per share were 3.16 yuan, reflecting a growth of 17.47% compared to the previous year [1] - In Q4, total revenue was 2.04 billion yuan, showing a year-on-year increase of 22.59% [1] - The net profit for Q4 was 332 million yuan, which is a significant growth of 39.27% year-on-year [1] Customer Base and Revenue Sources - The company added over 300 new clients during the reporting period [1] - Revenue from large pharmaceutical companies was 2.916 billion yuan, up 8.36% year-on-year [1] - Revenue from small and medium-sized pharmaceutical companies reached 3.755 billion yuan, increasing by 20.57% [1] - Revenue from overseas clients amounted to 4.921 billion yuan, reflecting a growth of 14.85% [1] - Revenue from domestic clients was 1.749 billion yuan, with a year-on-year growth of 15.09% [1]